Previous studies have shown that empagliflozin can effectively reduce lipid deposition and ameliorate nonalcoholic steatohepatitis via activating AMPK/FOXA2 signaling to upregulate MCAD expression; thus, MCAD may be a potential therapeutic target for the treatment of nonalcoholic steatohepatitis [27]. Here, FOXA2 is linked to metabolic dysfunction-associated steatohepatitis.